Javier Ampuero

Javier Ampuero

Auto-generated profile, based on publicly available information

Javier Ampuero

Hospital Universitario Virgen del Rocío Sevilla Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
MEMohammed Eslam
Mohammed Eslam
AHAhmed M Hashem
Ahmed M Hashem
RLReynold Leung
Reynold Leung
MRManuel Romero-Gómez
Manuel Romero-Gómez
TBT Berg
T Berg
RSRosanna Santaro
Rosanna Santaro
Tissue fibrosis is a core pathologic process that contributes to mortality in ~45% of the population and is likely to be influenced by the host genetic architecture. Here we demonstrate, using liver disease as a model, that a single-nucleotide polymorphism (rs12979860) in the intronic region of interferon-λ4 (IFNL4) is a strong predictor of fibrosis in an aetiology-independent manner. In a cohort of 4,172 patients, including 3,129 with chronic hepatitis C (CHC), 555 with chronic hepatitis B (CHB) and 488 with non-alcoholic fatty liver disease (NAFLD), those with rs12979860CC have greater hepatic inflammation and fibrosis. In CHC, those with rs12979860CC also have greater stage-constant and stage-specific fibrosis progression rates (P<0.0001 for all). The impact of rs12979860 genotypes on fibrosis is maximal in young females, especially those with HCV genotype 3. These findings establish rs12979860 genotype as a strong aetiology-independent predictor of tissue inflammation and fibrosis.

3 June 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
RYRamy Younes
Ramy Younes
Gian Paolo CavigliaGian Paolo Caviglia
Gian Paolo Caviglia
OGOlivier Govaere
Olivier Govaere
CRChiara Rosso
Chiara Rosso
Angelo ArmandiAngelo Armandi
Angelo Armandi
EBElisabetta Bugianesi
Elisabetta Bugianesi

1 January 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JAJavier Ampuero
Javier Ampuero
RPRaluca Pais
Raluca Pais
RFRocío Aller de la Fuente
Rocío Aller de la Fuente
RGRocio Gallego-Duran
Rocio Gallego-Duran
JCJavier Crespo
Javier Crespo
EMElvira del Pozo Maroto
Elvira del Pozo Maroto

1 June 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
JCJose Luis Calleja
Jose Luis Calleja
JCJavier Crespo
Javier Crespo
DRDiego Rincón
Diego Rincón
BRBELEN RUIZ-ANTORÁN
BELEN RUIZ-ANTORÁN
IFInmaculada Fernandez
Inmaculada Fernandez
ZMZoe Mariño
Zoe Mariño

1 November 2015 in Gastroenterology
Verified
Journal Article
Closed access
JAJavier Ampuero
Javier Ampuero
MSMacarena Simón
Macarena Simón
CMCarmina Montoliú
Carmina Montoliú
RJRodrigo Jover
Rodrigo Jover
MSMiguel Ángel Serra
Miguel Ángel Serra
MRManuel Romero-Gómez
Manuel Romero-Gómez

1 January 2013 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MRMaría Rojas-Feria
María Rojas-Feria
MCManuel Castro
Manuel Castro
ESEmilio Suárez
Emilio Suárez
JAJavier Ampuero
Javier Ampuero
MRManuel Romero-Gómez
Manuel Romero-Gómez
Abnormal liver biochemical tests are present in up to 30% of patients with inflammatory bowel disease (IBD), and therefore become a diagnostic challenge. Liver and biliary tract diseases are common extraintestinal manifestations for both Crohn's disease and ulcerative colitis (UC), and typically do not correlate with intestinal activity. Primary sclerosing cholangitis (PSC) is the most common hepatobiliary manifestation of IBD, and is more prevalent in UC. Approximately 5% of patients with UC develop PSC, with the prevalence reaching up to 90%. Cholangiocarcinoma and colon cancer risks are increased in these patients. Less common disorders include autoimmune hepatitis/PSC overlap syndrome, IgG4-associated cholangiopathy, primary biliary cirrhosis, hepatic amyloidosis, granulomatous hepatitis, cholelithiasis, portal vein thrombosis, liver abscess, and non-alcoholic fatty liver disease. Hepatitis B reactivation during immunosuppressive therapy is a major concern, with screening and vaccination being recommended in serologically negative cases for patients with IBD. Reactivation prophylaxis with entecavir or tenofovir for 6 to 12 mo after the end of immunosuppressive therapy is mandatory in patients showing as hepatitis B surface antigen (HBsAg) positive, independently from viral load. HBsAg negative and anti-HBc positive patients, with or without anti-HBs, should be closely monitored, measuring alanine aminotransferase and hepatitis B virus DNA within 12 mo after the end of therapy, and should be treated if the viral load increases. On the other hand, immunosuppressive therapy does not seem to promote reactivation of hepatitis C, and hepatitis C antiviral treatment does not influence IBD natural history either. Most of the drugs used for IBD treatment may induce hepatotoxicity, although the incidence of serious adverse events is low. Abnormalities in liver biochemical tests associated with aminosalicylates are uncommon and are usually not clinically relevant. Methotrexate-related hepatotoxicity has been described in 14% of patients with IBD, in a dose-dependent manner. Liver biopsy is not routinely recommended. Biologics-related hepatotoxicity is rare, but has been shown most frequently in patients treated with infliximab. Thiopurines have been associated with veno-occlusive disease, regenerative nodular hyperplasia, and liver peliosis. Routine liver biochemical tests are recommended, especially during the first month of treatment. All these conditions should be considered in IBD patients with clinical or biochemical features suggestive of hepatobiliary involvement. Diagnosis and management of these disorders usually involve hepatologists and gastroenterologists due to its complexity.